Though COVID-19 has killed Black Americans at nearly twice the rate as white Americans, Black people are the least likely racial group to say they’re eager to get the vaccine.
Academic rigour, journalistic flair
Articles on COVID-19 vaccines
Displaying 401 - 420 of 576 articles
A waiver may not allow all developing countries to secure medicines and other anti-COVID technologies in a timely way.
Two residents in a Brisbane aged-care home were given a higher dose of the Pfizer vaccine than recommended. Here’s what might have happened – and how we can reduce the risk it will happen again.
Years of vaccine research tells us that, if side effects are going to occur, they normally occur within the first months after getting a vaccine.
Australia’s keenly awaited COVID vaccine rollout begins today. So how will it work, and will the vaccine be the end of all our coronavirus-related problems?
In 1959, three armed men broke into the University of Montréal and stole the whole supply of polio vaccine — 75,000 vials valued at $50,000. What have we learned from this event?
Some evidence suggests the immune response to asthma may offer some protection against COVID.
It is possible to be an ethical vegan, who supports a better world for animals, and have the COVID-19 vaccine.
The anti-vaccine movement is the product of a structural problem, reflecting a lack of trust in the existing global vaccine governance.
Plus new research on why China is closing down coal-fired power stations. Listen to episode 3 of The Conversation Weekly.
The clock starts ticking once the vaccine leaves the freezer. Here’s what to expect.
Facebook’s decision to ban media organisations from posting links to news articles on the social media giant’s platform comes under a week before Australia’s COVID vaccine rollout begins.
The Pfizer vaccine rolls out to high-risk people in Australia from next week. And many of these front-line workers will be women. Here’s what we know so far.
With the COVID-19 vaccine soon to be rolled out in Australia, there are situations where proof of vaccination may be required.
When people start to hear that global case numbers are improving, there’s a tendency to relax — and that’s risky.
How will governments convince enough people to get vaccinated to achieve herd immunity?
People with disabilities are overlooked for COVID-19 vaccine distribution and triage protocols. We need to make this group a priority and address issues that put them at risk.
Australia should pivot to a high-efficacy vaccine like Pfizer or Novavax to give us the best chance of achieving herd immunity.
The world’s most advanced economies will incur half the total costs associated with a failure to vaccinate poorer nations, which could exceed $4 trillion if only half their citizens are inoculated.
We can help vaccines keep up with the mutating coronavirus by doubling down on preventive measures.
Top contributors
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
